Abstract
3-O-Methyl-6-[18F]fluoro-l-DOPA (OMFD) is a major metabolite of 6-[18F]fluoro-L-DOPA. Although synthesis of OFMD was primarily established to study the dopaminergic system, as it is an amino acid analogue, uptake in experimental tumours has been found. The aim of this study was to evaluate the applicability of OMFD for brain tumour imaging and to obtain initial estimates of whole-body biodistribution and radiation dosimetry in humans. Nineteen patients with suspected or confirmed brain tumours were investigated with OMFD and dynamic brain PET, complemented by whole-body PET in seven patients. Tracer kinetics were compared for normal brain and intracerebral lesions. Tissue accumulation was quantified with standardised uptake values (SUVs). Whole-body distribution in combination with tracer kinetics from animal experiments was used for the calculation of radiation dosimetry data. On the basis of OMFD PET, viable brain tumour was suspected in 16 patients with SUVs of 3.0±0.8 and a tumour to non-tumour ratio of 1.9±0.5. Highest tumour and normal brain uptake occurred between 15 and 30 min, with a subsequent slow decrease. Late whole-body tracer distribution was uniform without specific organ accumulation. Elimination occurred via urine. The mean radiation dose to the whole body was estimated at 0.016 mSv/MBq, with the kidneys as dose-critical organ (0.033 mGy/MBq). In conclusion, OMFD enables the visualisation of brain tumours with SUVs similar to other fluorinated amino acids. The whole-body radiation exposure from OMFD is comparable to that from FDG imaging.
This is a preview of subscription content, log in via an institution to check access.
References
Reske SN, Kotzerke J. FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, "Onko-PET III", 21 July and 19 September 2000. Eur J Nucl Med 2001; 28:1707–1723.
Bodsch W, Coenen HH, Stocklin G, Takahashi K, Hossmann KA. Biochemical and autoradiographic study of cerebral protein synthesis with [18F]-and [14C]fluorophenylalanine. J Neurochem 1988; 50:979–983.
Coenen HH, Kling P, Stocklin G. Cerebral metabolism ofl-[2-18F]fluorotyrosine, a new PET tracer of protein synthesis. J Nucl Med 1989; 30:1367–1372.
Inoue T, Tomiyoshi K, Higuichi T, et al. Biodistribution studies onl-3-[fluorine-18]fluoro-alpha-methyl tyrosine: a potential tumor-detecting agent. J Nucl Med 1998; 39:663–667.
Wester HJ, Herz M, Weber W, et al. Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-l-tyrosine for tumor imaging. J Nucl Med 1999; 40:205–212.
Füchtner F, Steinbach J. Efficient synthesis of the18F-labeled amino acid 3-O-methyl-6-[18F]fluoro-l-DOPA. Appl Radiat Isot 2003; 58:575–578.
Mejia AA, Nakamura T, Masatoshi I, Hatazawa J, Masaki M, Watanuki S. Estimation of absorbed doses in humans due to intravenous administration of fluorine-18-fluorodeoxyglucose in PET studies. J Nucl Med 1991; 32:699–706.
Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 1996; 37:538–546.
Bauer R, Brust P, Walter B, et al. Relation between brain tissue pO2 and dopamine synthesis of basal ganglia—a18FDOPA-PET study in newborn piglets. J Perinat Med 2000; 28:54–60.
Füchtner F, Steinbach J, Vorwieger G. 3-O-Methyl-6-[18F]fluoro-l-dopa—a promising substance for tumour imaging. J Lab Compd Radiopharm 1999; 42 Suppl 1: S267–S269.
Weber WA, Wester HJ, Grosu AL, et al. O-(2-[18F]fluoroethyl)-l-tyrosine and l-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study. Eur J Nucl Med 2000; 27:542–549.
Inoue T, Shibasaki T, Oriuchi N, et al.18F alpha-methyl tyrosine PET studies in patients with brain tumors. J Nucl Med 1999; 40:399–405.
Wahl L, Chirakal R, Firnau G, Garnett ES, Nahmias C. The distribution and kinetics of [18F]6-fluoro-3-O-methyl-l-dopa in the human brain. J Cereb Blood Flow Metab 1994; 14:664–670.
Rivera-Calimlin L. Absorption, metabolism and distribution of [14C]-O-methyldopa and [14C]-l-dopa after oral administration in rats. Br J Pharmacol 1974; 50:259–263.
Doudet DJ, McLellan CA, Carson R, et al. Distribution and kinetics of 3-O-methyl-6-[18F]fluoro-l-dopa in the rhesus monkey brain. J Cereb Blood Flow Metab 1991; 11:726–734.
Hays MT, Watson EE, Thomas SR, Stabin M. MIRD dose estimate report no. 19: radiation absorbed dose estimates from18F-FDG. J Nucl Med 2002; 43:210–214.
Deloar HM, Fujiwara T, Nakamura T, et al. Estimation of internal absorbed dose ofl-[methyl-11C]methionine using whole-body positron emission tomography. Eur J Nucl Med 1998; 25:629–633.
Rau FC, Weber WA, Wester HJ, et al. O-(2-[18F]Fluoroethyl)-l-tyrosine (FET): a tracer for differentiation of tumour from inflammation in murine lymph nodes. Eur J Nucl Med Mol Imaging 2002; 29:1039–1046.
Watanabe H, Inoue T, Shinozaki T, et al. PET imaging of musculoskeletal tumours with fluorine-18 alpha-methyltyrosine: comparison with fluorine-18 fluorodeoxyglucose PET. Eur J Nucl Med 2000; 27:1509–1517.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Beuthien-Baumann, B., Bredow, J., Burchert, W. et al. 3-O-Methyl-6-[18F]fluoro-l-DOPA and its evaluation in brain tumour imaging. Eur J Nucl Med Mol Imaging 30, 1004–1008 (2003). https://doi.org/10.1007/s00259-003-1205-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00259-003-1205-2